We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Lab
Dr. Josep Tabernero, Dr. Enriqueta Felip, Dr. Ana Oaknin, Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré, Dr. Jaume Sastre Garriga and Dr. Elena Élez have been recognised in the ranking.
Clarivate™ has today released its annual list of Highly Cited Researchers™ 2025. This small fraction of the global scientific community makes an outstanding contribution to expanding the frontiers of knowledge and driving innovations that make the world healthier, more sustainable and socially impactful. Among them are eight professionals from the Vall d’Hebron Campus.
For 2025, Dr. Josep Tabernero, Dr. Enriqueta Felip and Dr. Ana Oaknin, from the Vall d’Hebron Institute of Oncology (VHIO), have been recognised in the Clinical Medicine category.
“I am thrilled to have been listed as a Highly Cited Researcher 2025. This recognition is not about individual contributions or achievements, but the result of cross-border team science of excellence, conducted in collaboration with many leading research centers including VHIO. These precious partnerships enable the international oncology community to gain continued wins against cancer,” said Dr. Josep Tabernero, VHIO’s Director and Head of the Medical Oncology Department at the Vall d’Hebron University Hospital.
“I couldn’t agree more,” added Dr. Enriqueta Felip, Head of the Thoracic Cancer Unit at the Vall d’Hebron University Hospital and of the Thoracic Tumors Group and co-Director of Clinical Research at VHIO. “I am privileged to work alongside so many other dedicated colleagues and hugely talented investigators nationally and globally. It is thanks to the extraordinary efforts of our translational teams and talents, research partners, and other specialties that we continue to make important progress against this disease.”
“Collaboration in oncology is fundamental to addressing unmet clinical needs. While Highly Cited Researcher designation celebrates the work of individual investigators, impactful research in oncology is highly collaborative, counting on the collective work and shared dedication of healthcare teams and professionals who work together to improve outcomes for cancer patients,” observed Dr. Ana Oaknin, Head of the Gynecological Tumors Unit at Vall d’Hebron University Hospital and of the VHIO’s Gynecological Malignancies Group and.
In the Neurosciences and Behaviour category, Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré and Dr. Jaume Sastre Garriga, from the Vall d’Hebron Research Institute (VHIR), have been selected.
Dr. Xavier Montalban, Director of the Multiple Sclerosis Centre of Catalonia (Cemcat) and Head of the Clinical Neuroimmunology Group at VHIR, explained that “for me, the value of this recognition lies in the clinical applicability of our research and its potential benefit for patients.”
“Being recognised as a Highly Cited Researcher is an honour that reflects the collective impact of the translational research in neuroradiology carried out at Vall d’Hebron, aimed at improving patients’ lives,” highlighted Dr Álex Rovira, Head of Neuroradiology at Vall d’Hebron University Hospital and of the Neuroradiology Group at the VHIR.
“Science is a team effort. This recognition is the result of collaboration and a shared passion to better understand and treat people with multiple sclerosis,” said Dr. Mar Tintoré, Clinical Head of the Neurology Department at Vall d’Hebron University Hospital, Principal Investigator of the Clinical Neuroimmunology Group at VHIR and Clinical Head at Cemcat.
“This recognition is, above all, for our centre’s team, for our international collaborators and, most especially, for all the patients who actively take part in research. Without them, no progress in multiple sclerosis would be possible”, added Dr. Jaume Sastre Garriga, neurologist of the Vall d’Hebron University Hospital, Deputy Director of Cemcat and Principal Investigator of the Clinical Neuroimmunology Group at VHIR.
Dr. Elena Élez, Head of the Gastrointestinal Tumours Unit at Vall d’Hebron University Hospital and the Gastrointestinal and Colorectal Tumours Group at VHIO, has been included in the Cross-Field category, which recognises researchers whose work has a significant impact across multiple disciplines. “I am truly honored to have been designated as a Highly Cited Researcher for cross-field impact. Interdisciplinary collaboration is also key to advancing progress against cancer. By applying diverse perspectives, approaches, and technologies, we will continue to make significant headway in addressing the many unanswered questions in the field,” she said.
Since 2001, Clarivate has annually identified the small fraction of international scientists who have demonstrated significant and broad influence in their respective research fields.
Based on citation data, along with other quantitative metrics, qualitative analysis and expert judgement, the team at Clarivate’s Institute for Scientific Information (ISI) compiles this list each year.
This year, Clarivate has recognised 6,868 researchers, with a total of 7,131 mentions, from over 1,300 institutions across 61 countries and regions. The total number of designations exceeds that of individual researchers, as some have been recognised in more than one field of the Essential Science Indicators (ESI).
The full list is available at this link.
Clarivate identifies each year the small fraction of international scientists who have demonstrated significant and wide-ranging influence in their respective fields of research
Director, Vall d’Hebron Institute of Oncology
Medical Oncology, General Hospital
Neurology, General Hospital
Radiodiagnosis (IDI), General Hospital
Clinical neuroimmunology, General Hospital
Neurologist, Multiple Sclerosis Centre of Catalonia
Elena Élez is an attending phisicyan of the Gastrointestinal Tumors Service of the Medical Oncology Service of the Vall d'Hebron University Hospital. She is currently also Principal Investigator of the Gastrointestinal Tumor Group and Endocrine of VHIO, headed by Josep Tabernero, director of VHIO.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.